Back to search results

Understanding Metabolism in Chronic Lymphocytic Leukemia (CLL)

This observational study aims to understand how normal cells and chronic lymphocytic leukemia (CLL) cells use energy. Researchers will give participants two special types of sugar and amino acid: [U-13C]glucose and [13C5]glutamine. These are labeled so scientists can track how they are used by cells. The study wants to see how much of these substances are taken up by normal and leukemic lymphocytes (a type of white blood cell) within two hours. This information could help identify new ways to treat CLL. You may be eligible if you are an adult with no prior cancer history and normal blood counts, or an adult with a low-burden CLL diagnosis. The study plans to enroll 16 participants, but its current status is unclear.

Study design
This is an observational study, meaning researchers will observe and collect data without assigning treatments. It plans to include 16 adult participants.
What's involved
You will receive [U-13C]glucose and [13C5]glutamine as infusions over about two hours. Blood samples will be taken during this time to measure how these substances are used.
Compensation
Not stated in the trial record.
Follow-up
Measurements will be taken up to two hours after the infusions.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT04785989

In Vivo Metabolic Profiling of CLL (Chronic Lymphocytic Leukemia)

Recruiting
Not specifiedAges 18+Observational
University of Wisconsin, Madison
~16 participants
Updated 2025-11-26 on ClinicalTrials.gov
What's tested:[U-13C]glucose[13C5]glutamine

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Amount of [U-13C]glucose incorporation into metabolites in normal and leukemic lymphocytes: Liquid chromatography-mass spectrometry (LCMS) pharmacokinetic analysis
Measured over up to 2 hours (± 5 minutes)
+1 more outcome measured

Conditions

Chronic Lymphocytic Leukemia

Explore related trials

Chronic Lymphocytic LeukemiaHealthyHematologic Neoplasm

NCT04785989

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • University of Wisconsin

    Madison, Wisconsinno site contact published

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Christopher Fletcher, MD · PRINCIPAL_INVESTIGATOR · School of Medicine and Public Health, University of Wisconsin, Madison

Who to contact

Cancer Connect
[email protected]
800-622-8922
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Adult (18 years of age or older)
No previous history of cancer
Routine history of normal blood counts and vital signs
Documented Informed Consent
Adult (18 years of age or older)
Diagnosis of CLL with low disease burden defined as Rai stage 0 ((Lymphocytosis; no enlargement of the lymph nodes, spleen, or liver; red blood cell and platelet counts are near normal.)
Treatment naïve
Documented Informed Consent
Adult (18 years of age or older)
Diagnosis of CLL with high systemic disease burden defined as infiltration of bone marrow causing cytopenia
Treatment naïve
Able/willing to have bone marrow aspiration
Documented Informed Consent

Exclusion

Prisoners
Psychiatric inpatients or people who are institutionalized
Minor (Less than 18 years of age)
History of diabetes
Cannot be on antihyperglycemic therapy
Carbohydrate restricting diets: Atkins, Vegan, Ketogenic, etc.
Females of child bearing potential
Persons without decision-making capacity
Person who cannot read/write English

What this trial measures

  • Amount of [U-13C]glucose incorporation into metabolites in normal and leukemic lymphocytes: Liquid chromatography-mass spectrometry (LCMS) pharmacokinetic analysisup to 2 hours (± 5 minutes)

    It will reveal how CLL cells utilize glucose compared to non-leukemic lymphocytes and how this changes with different disease burden and site of disease. Participants will be on overnight fasting.

  • Amount of [U-13C15N]L-glutamine incorporation into metabolites in normal and leukemic lymphocytes: LCMS pharmacokinetic analysisup to 2 hours (± 5 minutes)

    It will reveal how CLL cells utilize glutamine compared to non-leukemic lymphocytes and how this changes with different disease burden and site of disease. Participants will be on overnight fasting.